Cell Signaling Technology

Rac1/2/3 Antibody

#2465 · $136

100
Citing papers
21.9k
Combined citations
Supplier page Find this product

Research areas

Cancer Immunotherapy and Biomarkers19CAR-T cell therapy research10Metabolism, Diabetes, and Cancer9Immunotherapy and Immune Responses9Immune Cell Function and Interaction9Cancer-related Molecular Pathways8Cancer, Hypoxia, and Metabolism7PI3K/AKT/mTOR signaling in cancer5

Papers citing this product

1
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer
JAMA Oncology·2015·834 cit.·DOI
2
The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis
Journal of Clinical Investigation·2005·696 cit.·DOI
3
Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression
Journal of Clinical Investigation·2018·598 cit.·DOI
4
Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation
JCI Insight·2018·573 cit.·DOI
5
ZO-1 controls endothelial adherens junctions, cell–cell tension, angiogenesis, and barrier formation
The Journal of Cell Biology·2015·572 cit.·DOI
6
Cancer-associated fibroblasts induce antigen-specific deletion of CD8 + T Cells to protect tumour cells
Nature Communications·2018·558 cit.·DOI
7
p27 <sup>Kip1</sup> modulates cell migration through the regulation of RhoA activation
Genes & Development·2004·487 cit.·DOI
8
Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T cells
The Journal of Experimental Medicine·2015·452 cit.·DOI
9
EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy
Oncotarget·2014·386 cit.·DOI
10
Apoptosis Induced by the Toll-Like Receptor Adaptor TRIF Is Dependent on Its Receptor Interacting Protein Homotypic Interaction Motif
The Journal of Immunology·2005·365 cit.·DOI
Rac1/2/3 Antibody — Evidence — PubIndex